Osiris Therapeutics designated as Orphan Drug title holder by EMA Osiris Therapeutics announced that the European Medicines Agency, or EMA, has designated Osiris as the Orphan Drug title holder for Prochymal. The EU Commission adopted the decision to transfer the designation of Prochymal as an orphan medicinal product under Regulation, or EC, No 141/2000 of the European Parliament and of the Council. The Decision will appear in the EU Community Register of Orphan Medicinal Products.
Osiris assumed with a Hold from Buy at Brean Capital Brean Capital analyst Jason Wittes downgraded Osiris Therapeutics (OSIR) to Hold after assuming coverage of the name. The analyst views the stock as fairly valued at current levels and sees increased competition from Integra LifeSciences' (IART) entry into the diabetic foot ulcer market.